Stem cells and regenerative medicine are moving from the laboratory to clinical practice, from concept validation to industrial implementation. Whether it is the large-scale application of mesenchymal stem cells, clinical breakthroughs in tissue-specific stem cells, technological iterations of iPS derived cardiomyocytes, hematopoietic stem cells, and NK cells, or even new explorations in vivo gene editing, this field is ushering in a golden window driven by both technology and policy.

The complete schedule of the "Stem Cell and Regenerative Medicine New Technology Special Session" was officially released today. The special session gathers top scientists, clinical experts, and industry pioneers in the field of stem cells, focusing on cutting-edge directions such as MSCs, lung and kidney tissue stem cells, liver stem cells and artificial liver, iPS derived cardiac drugs and immune cells, gene edited stem cells, etc., to deeply explore technological breakthroughs, clinical transformation paths, and domestic opportunities in industrial supply chains.
 

From July 22nd to 24th, at the Shanghai National Convention and Exhibition Center, we look forward to exploring the new future of stem cells and regenerative medicine with you.

Scan the code to register immediately
Early bird tickets are available for a limited time at a 25% discount!!

// Session Schedule//
Co-organized by:VCANBIO;Session Co-organized by:ExCell Bio

13:30-17:40 / 23rd

13:30-13:45　Opening Remarks
Hongjia Gong: Co-founder of Hikvision, Founder of Jiadao Capital, Controlling Shareholder and Chairman of VCANBIO
Lijian Hui: President of the Cell and Gene Therapy Division, Chinese Society for Cell Biology; Professor at the Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences

13:45-14:00　iPSC-Derived Hematopoietic Stem Cells and NK Cells
Qijing Li: Director of the Cell and Gene Therapy Center, Agency for Science, Technology and Research (A*STAR), Singapore

14:00-14:20　Regulatory Framework and Latest Updates of Regenerative Medical Products at Japan PMDA
Yoshiaki Maruyama: Director of the Office of Cellular and Tissue-based Products, Pharmaceuticals and Medical Devices Agency (PMDA), Japan

14:20-14:30　Launch Session: Global Blue Book on Stem Cell Drug Industry Development

14:30-14:45　Industry and MSCs
Yu Zhang:Director and Co-President of VCANBIO, Chairman of the CGT Club of Tongxieyi

14:45-15:25　Panel Discussion 1: Stem Cell Therapy Clinical Translation Chain — Opportunities under New Policies
Chenyan Gao: Director of the Biologics Clinical Division, Center for Drug Evaluation, National Medical Products Administration (NMPA)
Zhenbo Su: CEO of TCRCure
Yingchi Zhang: Cellular Product Qualified Person, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences; Head of Technology Transfer Office, Haihe Laboratory of Cell Ecosystem
Wensong Tan: Founder and Chairman of Shanghai Bioengine Biotechnology
Hongming Tang: Deputy Director of the National Stem Cell Translational Resource Center; Director of the Stem Cell Clinical Translational Research Office, Shanghai East Hospital, Tongji University

15:25-15:45　Break

15:45-16:00　The Clinical Leap of Gene Editing
Wensheng Wei: Professor at the School of Life Sciences, Peking University

16:00-16:15　TBD

16:15-16:30　Multi-Organ Regeneration and Repair Based on Epithelial Tissue Stem Cells — From Evolutionary Biology to Smart Cellular Manufacturing
Wei Zuo: Chairman of Regend Therapeutics, Professor at Tongji University

16:30-16:45　Stem Cells and Bioartificial Liver: From Liver Protection to Liver Regeneration
Guoyu Pan: Chairman of Shanghai MicroZhizhuo Biotechnology

16:45-17:00　Process Analysis of Large-Scale iPSC Culture
Juan Hou: Dean of the ExCell Future Institute

17:00-17:40　Panel Discussion 2: Stem Cell Product Supply Chain — Opportunities for Localization
Xu Chen: Founder, Chairman and President of ExCell Bio
Wei Liu: Co-founder and CEO of CytoNiche
Feng Zhang: CEO of Lead Healthcare.AI
Weihua Huang: Chairman and CEO of Yeasen Biotechnology
Jingwen Tao: Assistant to the President, Director of the AI Innovation Center, Mind-AI